Surufatinib combined with anti-PD-1/PD-L1 antibody in the second-line or monotherapy in third-line treatment of advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study

被引：0
|
作者：
Zhou, F. [1 ]
Yang, L. [1 ]
Peng, J. [1 ]
Xu, H. [1 ]
Wu, H. [1 ]
Wang, Y. [1 ]
Long, X. [1 ]
Gao, Q. [2 ]
Shi, X. [3 ]
Gong, J. [4 ]
Hu, J. [3 ]
机构：
[1] Wuhan Univ, Zhongnan Hosp, Dept Radiat Oncol Med Oncol, Hubei Canc Clin Study Ctr, Wuhan, Peoples R China
[2] Huangmei Cty Peoples Hosp, Dept Radiat Oncol, Huanggang, Peoples R China
[3] Macheng Peoples Hosp, Dept Med Oncol, Macheng, Peoples R China
[4] Huangshi Cent Hosp, Dept Med Oncol, Huangshi, Hubei, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
974P
引用
收藏
页码：S668 / S668
页数：1
相关论文
共 50 条
  • [1] Combining radiation therapy with anti-PD-1 for patients with advanced hepatocellular carcinoma: An open-label, single-center, single-arm clinical study.
    Li, Jian-Xu
    Su, Ting-Shi
    Lin, Xiao-Feng
    Chen, Yi-Tian
    Liang, Shi-Xiong
    Xiang, Bang-De
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Efficacy and safety of PD-1/PD-L1 antibody combined with chemotherapy as second-line or third-line treatment for metastatic small cell lung cancer.
    Wang, Jun
    Yin, Beibei
    Guan, Yaping
    Feng, Dongfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study
    Cheng, Yu
    Teng, Zan
    Zhang, Yanqiao
    Jin, Bo
    Zheng, Zhendong
    Man, Li
    Wang, Zhenghua
    Teng, Yuee
    Yu, Ping
    Shi, Jing
    Luo, Ying
    Wang, Ying
    Zhang, Jingdong
    Zhang, Huijuan
    Liu, Jiwei
    Chen, Hao
    Xiao, Jiawen
    Zhao, Lei
    Zhang, Lingyun
    Jiang, Yu
    Chen, Ying
    Zhang, Jian
    Wang, Chang
    Liu, Sa
    Qu, Jinglei
    Qu, Xiujuan
    Liu, Yunpeng
    BMC CANCER, 2024, 24 (01)
  • [4] Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study
    Wang Feng
    Wang Junsheng
    Wu Tao
    Hong Yonggui
    Meng Xiangrui
    Ren Zhonghai
    Guo Yanzhen
    Yang Xiuli
    Shi Pei
    Yang Jiamei
    Fan Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [5] Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer
    de Liano Lista, Alfonso Gomez
    van Dijk, Nick
    Oria de Rueda, Guillermo de Velasco
    Necchi, Andrea
    Lavaud, Pernelle
    Morales-Barrera, Rafael
    Alonso Gordoa, Teresa
    Maroto, Pablo
    Ravaud, Alain
    Duran, Ignacio
    Szabados, Bernadett
    Castellano, Daniel
    Giannatempo, Patrizia
    Loriot, Yohann
    Carles, Joan
    Anguera Palacios, Georgia
    Lefort, Felix
    Raggi, Daniele
    Goupil, Marine Gross
    Powles, Thomas
    Van der Heijden, Michiel S.
    EUROPEAN UROLOGY, 2020, 77 (02) : 269 - 276
  • [6] Camrelizumab monotherapy or plus apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A single-arm, open-label, multicenter, phase II study
    Zhao, M.
    Liu, X.
    Yuan, C.
    Zheng, W.
    Zhang, D.
    Long, Q.
    Li, J.
    Han, T.
    Xu, L.
    Li, H.
    Li, X.
    Shi, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S36 - S37
  • [7] Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
    Finn, Richard S.
    Kang, Yoon-Koo
    Mulcahy, Mary
    Polite, Blase N.
    Lim, Ho Yeong
    Walters, Ian
    Baudelet, Christine
    Manekas, Demetrios
    Park, Joong-Won
    CLINICAL CANCER RESEARCH, 2012, 18 (07) : 2090 - 2098
  • [8] Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies
    Hamid, O.
    Chow, L. Q.
    Sanborn, R. E.
    Marshall, S.
    Black, C.
    Gribbin, M.
    McDevitt, J.
    Karakunnel, J. J.
    Gray, J. E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Camrelizumab monotherapy or in combination with apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A multicenter, open-label, single-arm, phase II study.
    Zhao, Mingfang
    Han, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] A Single-Arm Multi-Center Phase II Study of Apatinib in Patients with ES-SCLC After Second/Third-Line Chemotherapy
    Fan, Y.
    Huang, Z.
    Li, W.
    Li, Y.
    Chen, J.
    Xu, Y.
    Lu, H.
    Yu, X.
    Xu, Y.
    Qin, J.
    Jin, Y.
    Xu, X.
    Gong, L.
    Xie, F.
    Han, N.
    Zhang, P.
    Chen, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S573 - S573
12345